企業を読み込み中
Keep exploring
The themes Novo Nordisk A/S is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The themes it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company$1.36TA+
JNJJohnson & Johnson$688.6BA+
MRKMerck & Co., Inc.$364.3BA
NVSNovartis AG$306.3BA
AMGNAmgen Inc.$251.9BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
どうやって稼いでいるか
- Sales of prescription medicines for diabetes, obesity and other conditions
競合
何を売っているか3
Wegovy injection
An injectable semaglutide medicine used for weight management.
Wegovy pill
A once-daily semaglutide pill used for weight management.
Ozempic
An injectable semaglutide medicine for type 2 diabetes.
誰が買っているか3
- People with diabetes or obesity who obtain medicines through a prescription or buy them directly in self-pay channels.
- Pharmacies and telehealth providers that supply medicines to patients.
- Private insurers and public programs that cover prescription medicines, including Medicare Part D in the United States.
何に支えられ、何に崩されうるか
事業が頼っているもの
- 1Recent sales growth and product launches rely on glucagon-like peptide-1 (GLP-1) medicines, including semaglutide brands such as Wegovy and Ozempic.
- 2Access to obesity medicines in the United States depends on insurance coverage and what patients can afford to pay themselves; the company said most Wegovy pill prescriptions there were self-pay in Q2 2026.
- 3Commercial supply depends on manufacturing capacity; the company said its new active pharmaceutical ingredient facilities were contributing very little commercial supply in Q2 2026.
うまくいかなくなる可能性
- 1Competition and lower realized prices can reduce sales from obesity and diabetes medicines; the company cited intensifying United States competition and pricing pressure in Q2 2026.
- 2Generic versions of semaglutide can reduce sales where patent protection expires; the company reported early generic entries in some international markets.
- 3Cybersecurity breaches could disrupt the business.
Novo Nordisk A/Sについて
Novo Nordisk makes medicines for diabetes and obesity, including Wegovy for weight management and Ozempic for type 2 diabetes. Its medicines reach patients through healthcare providers and pharmacies, with payment coming from insurers and public health programs or directly from patients. It also develops medicines for other conditions, including rare diseases.
- 本社
- Bagsværd, Denmark
- 設立
- 1923
- 従業員数
- around 66,700 (Q2 2026, medium)
- 上場市場
- New York Stock Exchange
- 決算期
- December 31
Novo Nordisk A/S 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 この企業は DKK で開示しています。数字は現在のレート $1.00 = 6.7640 DKK で米ドルに換算し、すべての期間に同じレートを適用しています——したがって成長率や利益率は企業自身のものであり、為替のものではありません。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。
